MAR Research Update — September 29, 2026
Updated Thesis
Marriott International is the world's largest hotel company by room count, operating an asset-light model that manages, franchises, and licenses roughly 30 brands across nearly 8,000 properties in 139 countries and territories, with 414,000 employees supporting the system. The business quality is high on cash generation but carries meaningful balance-sheet and cyclicality caveats: TTM operating margin is 15.8%, TTM net margin is 9.6%, and free cash flow per share is $11.66, yet ROE is deeply negative at -66.7% because of a large debt load and buyback-reduced equity, and debt stood at $16.915 billion at June 30, 2026, up from $16.204 billion at December 31, 2025. Growth has slowed to a mature pace, with revenue up 4.8% and earnings up 0.4% in the most recent quarter, and the shares trade at 37.22 times trailing earnings, 30.74 times free cash flow, 23.5 times EV/EBITDA, and 3.48 times sales, a regime the data labels expensive versus five-year history.
The investment grade as of this refresh is C — average business quality. B-tier business, C-tier valuation with 10.9% upside to $397.63 fair value.
Key Metrics at a Glance
- Revenue growth: +4.8% year over year
- Net margin: 9.6%
- Fair value upside: +10.9% to our estimate of $398
Current price: $358.57
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Marriott International, Inc. remains in our covered universe with a average-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full MAR research →](/stocks/MAR)